Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Mark Paul Lappe | CEO, President & Chairman | -- | -- | 1967 |
| Ms. Kelly Devine Deck B.S., CPA, M.S. | Executive VP, CFO & Treasurer | -- | -- | 1980 |
| Ms. Bonne Adams M.B.A. | Vice President of Operations | -- | -- | 1977 |
| Dr. Ashraf Amanullah Ph.D. | Executive VP, Chief Technical Operations Officer | -- | -- | 1968 |
| Dr. Brendan P. Eckelman Ph.D. | Executive VP & Chief Scientific Officer | -- | -- | 1979 |
| Ms. Leah Pollema J.D. | VP & General Counsel | -- | -- | -- |
| Dr. Charbel Helaihel Pharm.D. | Vice President of Marketing & Commercial Planning | -- | -- | -- |
| Mr. Jeffrey J. Jensen | Executive VP & Chief Clinical Operations Officer | -- | -- | -- |
| Dr. Josep Garcia Ph.D. | Executive VP & Chief Clinical Development Officer | -- | -- | -- |
| Mr. David Matly M.B.A. | Executive VP and Chief Commercial & Business Development Officer | -- | -- | -- |
Inhibrx Biosciences, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 166
Description
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
Corporate Governance
Upcoming Events
November 14, 2024 at 9:24 PM UTC
Inhibrx Biosciences, Inc. Earnings Date
Recent Events
June 14, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
May 22, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission